EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
EyePoint Inc (EYPT) shares fell 82% premarket after its lead drug, DURAVYU, failed a Phase 3 trial for wet AMD. The company will cut 53% of its workforce and pivot to diabetic macular edema trials. EyePoint has $118M in cash to fund operations until 2027.
How this was made
The 30-second read
Why it matters
The failure eliminates a major revenue opportunity and forces a strategic shift, likely triggering a sharp sell‑off.
Market read
Primary biotech news with immediate price impact; relevant for short‑term traders and sector risk assessment.
What to watch
Cash runway of $118 M may support continued R&D, and the pivot to diabetic macular edema could unlock new value.
Background
EyePoint is a Nasdaq‑listed biotech focused on ocular therapies. The LUCIA trial was its lead wet AMD study.
Ticker impact
EyePoint Inc reported its pivotal Phase 3 wet AMD trial failed, causing an 82% pre‑market plunge and a 53% workforce cut.
likely pressure as the market prices in the failed trial and restructuring news
First disclosure of a pivotal trial miss; investors will reassess the pipeline and cut valuation.
Market effects
Wet AMD biotech segment may see broader risk reassessment, potentially affecting peers with similar pipelines.
US biotech market could see modest downside as investors re‑evaluate trial‑risk exposure.
Limited to biotech investors; no broad macro impact.
Counterpoint
If the DME trials succeed, the company could rebound, making the sell‑off an overreaction.
Key entities
- companyEyePoint Inc
Nasdaq‑listed biotech developing ocular drugs.
